Memorial Sloan Kettering Cancer Center 10th Annual MSK Symposium on Lymphoma 2026

Advanced Updates in Lymphoma Diagnosis, Classification & Precision Oncology

The 10th Annual MSK Symposium on Lymphoma 2026 marks a decade of excellence in lymphoma education, bringing together internationally recognized experts in hematology, oncology, pathology, and translational research. Hosted by Memorial Sloan Kettering Cancer Center (MSKCC), this one-and-a-half-day symposium provides a comprehensive review of the rapidly evolving landscape of lymphoma diagnosis, classification, disease biology, and therapeutic innovation.

Designed for clinicians involved in the care of patients with lymphoma, the program explores recent advances in the WHO and International Consensus Classification (ICC) systems, emerging biomarkers, novel targeted therapies, cellular immunotherapies, and management strategies for both newly diagnosed and relapsed/refractory lymphoma.

Through keynote presentations, case-based panel discussions, and expert clinical guidance, participants gain practical insights into applying the latest scientific discoveries to individualized patient care.

Product Details

• Course: 10th Annual MSK Symposium on Lymphoma
• Provider: Memorial Sloan Kettering Cancer Center (MSKCC)
• Course Dates: April 10–11, 2026
• Location: Zuckerman Research Center, New York, NY
• Format: In-Person & Virtual
• Course Year: 2026

Program Overview

This advanced lymphoma symposium provides state-of-the-art updates across the spectrum of lymphoma care.

Key areas of focus include:

• Lymphoma Biology
• WHO & ICC Lymphoma Classification Updates
• Diagnostic Hematopathology
• B-Cell Lymphomas
• T-Cell Lymphomas
• Hodgkin Lymphoma
• Relapsed/Refractory Disease
• Targeted Therapies
• Immunotherapy
• Bispecific Antibodies
• CAR T-Cell Therapy
• Precision Medicine
• Shared Decision-Making
• Translational Research

The curriculum bridges emerging scientific discoveries with real-world clinical application.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Apply updated WHO and ICC lymphoma classification systems in clinical practice.
• Evaluate current first-line treatment strategies for common lymphoma subtypes.
• Discuss the mechanisms of action, efficacy, and toxicity profiles of novel lymphoma therapies.
• Implement evidence-based approaches for relapsed and refractory lymphoma.
• Incorporate precision medicine strategies into lymphoma management.
• Utilize shared decision-making principles to optimize treatment planning.
• Recognize emerging developments in lymphoma biology and translational research.
• Improve multidisciplinary collaboration in lymphoma care.

Core Topics Covered

Lymphoma Classification Updates

The course reviews major developments in:

• WHO Classification Updates
• International Consensus Classification (ICC)
• Molecular Diagnostics
• Biomarker Integration
• Disease Subtyping

Participants learn how modern classification systems influence diagnosis and treatment selection.

B-Cell Lymphomas

Comprehensive sessions explore:

• Diffuse Large B-Cell Lymphoma (DLBCL)
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Aggressive B-cell Neoplasms

Experts discuss evolving treatment paradigms and risk-adapted strategies.

Hodgkin Lymphoma

Topics include:

• Frontline therapy
• Risk stratification
• PET-guided management
• Novel immunotherapies
• Relapsed disease management

Faculty review current standards and future directions in care.

T-Cell & Rare Lymphomas

Specialized discussions address:

• Peripheral T-cell lymphomas
• Cutaneous lymphomas
• Rare lymphoma subtypes
• Diagnostic challenges
• Emerging treatment options

Participants gain practical insights into managing uncommon and complex cases.

Novel Therapeutics

The symposium highlights:

• Bispecific antibodies
• Antibody-drug conjugates
• Small molecule inhibitors
• Targeted therapies
• Immunotherapy combinations

Experts review efficacy data and toxicity management strategies.

CAR T-Cell Therapy

Sessions focus on:

• Patient selection
• Cellular therapy logistics
• Response assessment
• Cytokine release syndrome (CRS)
• Neurotoxicity management
• Long-term outcomes

Participants gain updates on one of the most rapidly evolving areas in lymphoma care.

Relapsed & Refractory Lymphoma

Key discussions include:

• Treatment sequencing
• Salvage therapy
• Cellular therapy integration
• Clinical trial opportunities
• Personalized treatment strategies

Faculty review approaches for difficult-to-treat lymphoma cases.

Precision Medicine & Translational Research

Topics include:

• Genomic profiling
• Molecular biomarkers
• Predictive testing
• Target discovery
• Future therapeutic directions

The program highlights how advances in biology are transforming patient care.

Shared Decision-Making

Participants learn strategies for:

• Patient-centered communication
• Treatment goal discussions
• Risk-benefit assessment
• Survivorship planning
• Long-term care coordination

Practical guidance is provided for individualized treatment planning.

Educational Features

✔ International Lymphoma Experts

✔ WHO & ICC Classification Updates

✔ Precision Oncology Applications

✔ CAR T-Cell Therapy Advances

✔ Bispecific Antibody Updates

✔ Case-Based Panel Discussions

✔ Translational Research Highlights

✔ Multidisciplinary Clinical Perspectives

Target Audience

This course is ideal for:

• Hematologists
• Medical Oncologists
• Radiation Oncologists
• Hematopathologists
• Internal Medicine Physicians
• Oncology Fellows
• Hematology Fellows
• Pathologists
• Advanced Practice Providers
• Oncology Pharmacists
• Researchers & Scientists
• Medical Trainees

Why This Course Stands Out

✔ Celebrates the 10th anniversary of MSK’s premier lymphoma symposium

✔ Features internationally recognized lymphoma experts

✔ Comprehensive review of modern lymphoma classification systems

✔ Strong focus on emerging therapies and precision medicine

✔ Covers both common and rare lymphoma subtypes

✔ Includes practical guidance for relapsed and refractory disease

✔ Integrates pathology, translational science, and clinical oncology

✔ Provides immediately applicable clinical insights

Clinical & Educational Value

The Memorial Sloan Kettering Cancer Center 10th Annual MSK Symposium on Lymphoma 2026 provides an in-depth review of the latest advances in lymphoma diagnosis, classification, and treatment. Through expert-led lectures, multidisciplinary discussions, and cutting-edge research updates, participants gain valuable knowledge on modern lymphoma management, novel therapeutics, cellular immunotherapy, and precision oncology. The course equips clinicians with the tools needed to deliver personalized, evidence-based care for patients with lymphoma.

Topics

1. A “Path” Toward Diagnosis- An Overview of Pathology in Lymphoma

2. Advances in Therapeutic Strategies for Mantle Cell Lymphoma

3. Bridging, Debulking, and Beyond- The Multifaceted Role of Radiotherapy with CAR T Cells and Bispecifics

4. CAR T-Cell Therapy- Lessons Learned from the DESCAR-T Registry

5. Concepts and Controversies in Aggressive B-Cell Lymphoma Classification

6. Current Challenges in the Management of Patients with Follicular Lymphoma

7. Debate- Is a Follicular Lymphoma Cure in Reach- T-Cell Engagers versus CAR T-Cell Therapy

8. Diffuse Large B-Cell Lymphoma- Diagnosis and Updates on Management

9. Diffuse Large B-Cell Lymphoma Panel Discussion and Q&A

10. Follicular Lymphoma Panel Discussion and Q&A

11. Hodgkin Lymphoma Panel Discussion and Q&A

12. HTLV-1 Clinic Overview

13. HTLV-1-Associated Lymphoma-Leukemia- Biology

14. HTLV-1-Associated Lymphoma-Leukemia- Epidemiology and Natural History

15. HTLV-1-Associated Lymphoma-Leukemia- Therapies

16. Innovations in T-Cell Lymphoma- A Winding Road

17. Insights into the Molecular Classification of Diffuse Large B-Cell Lymphoma

18. Integrative Medicine- Management of Treatment Related Side Effects

19. Introduction to Cutaneous T-Cell Lymphoma

20. Lessons Learned from the Development of T-Cell-Engaging Antibodies in B-Cell Lymphoma

21. Mantle Cell Lymphoma Panel Discussion and Q&A

22. Mechanisms of Resistance to BTK Degraders

23. Optimizing First-Line Therapy- Balancing Efficacy versus Toxicity

24. Optimizing First-Line Therapy in Diffuse Large B-Cell Lymphoma

25. Panel Discussion and Q&A

26. Plenary Lecture- Designing the Next Generation of CAR T-Cell Therapies for Lymphoma

27. Plenary Lecture Panel Discussion and Q&A

28. Recent Advances in the Management of Chronic Lymphocytic Leukemia

29. Research Spotlight- Bispecific B Cell Protocols at MSK and CRS management

30. Skin Considerations for Cutaneous T-Cell Lymphoma

31. Small Doses, Big Impact- The Role of Very Low-Dose Radiotherapy in Potentially Curable Indolent Lymphomas

32. Special Lecture- B-Cell Development and Lineage Stability

33. Special Lecture- How to Interpret “Real-World” Data

34. Spotlight on New Agents and MSK Clinical Trials

35. Spotlight on Nodular Lymphocyte Predominant B-Cell- Hodgkin Lymphoma

36. Spotlight on Recent Drugs and MSK Clinical Trials – 01

37. Spotlight on Recent Drugs and MSK Clinical Trials

38. T-Cell Lymphoma Panel Discussion and Q&A